1093.HK - CSPC Pharmaceutical Group Limited
| Previous Close | 15.640 |
| Open | 15.500 |
| Bid | 15.340 x 0 |
| Ask | 15.360 x 0 |
| Day's Range | 15.300 - 15.620 |
| 52 Week Range | 9.900 - 26.750 |
| Volume | 27,875,992 |
| Avg. Volume | 33,098,970 |
| Market Cap | 95.665B |
| Beta (3Y Monthly) | 0.72 |
| PE Ratio (TTM) | 26.20 |
| EPS (TTM) | 0.586 |
| Earnings Date | Aug 20, 2018 - Aug 24, 2018 |
| Forward Dividend & Yield | 0.18 (1.23%) |
| Ex-Dividend Date | 2019-05-30 |
| 1y Target Est | 20.92 |
- MarketWatch•4 days ago
Asian markets little changed as China’s economy holds steady
Asian stocks were mixed in a narrow range Wednesday as China announced its economy grew at a 6.4% annual pace in the last quarter.
- Reuters•8 days ago
BRIEF-CSPC Pharmaceutical Group Says "SYHA1803" Granted Clinical Trial Approval By NMPA China
April 12 (Reuters) - CSPC Pharmaceutical Group Ltd : * "SYHA1803" GRANTED APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA TO CONDUCT CLINICAL TRIALS IN CHINA Source text for Eikon: ...
- PR Newswire•last month
CSPC Pharmaceutical Announces 2018 Annual Results
HONG KONG, March 18, 2019 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (HKEx:01093) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company in China, is pleased to announce its annual results for the year ended 31 December 2018 (the "Year").
- Reuters•last month
BRIEF-CSPC Pharmaceutical Group Posts FY Profit Attributable Of HK$3.65 Bln
March 18 (Reuters) - CSPC Pharmaceutical Group Ltd : * FY PROFIT ATTRIBUTABLE HK$3.65 BILLION VERSUS HK$2.77 BILLION * FY REVENUE HK$21.03 BILLION VERSUS HK$15.46 BILLION * DECLARED A FINAL DIVIDEND PER ...
- Reuters•2 months ago
BRIEF-CSPC Pharmaceutical Submitted New Drug Application To U.S. FDA For Levoamlodipine Maleate Tablets
March 5 (Reuters) - CSPC Pharmaceutical Group Ltd: * SUBMITTED NEW DRUG APPLICATION TO U.S. FDA FOR LEVOAMLODIPINE MALEATE TABLETS FOR TREATMENT OF HYPERTENSION Source text for Eikon: Further company coverage:...
- Reuters•2 months ago
BRIEF-CSPC Pharmaceutical Group Says CSPC Innovation Pharmaceutical Proposed To Issue 50 Mln A Shares
March 5 (Reuters) - CSPC Pharmaceutical Group Ltd: * CSPC INNOVATION PHARMACEUTICAL CO., LTD PROPOSED TO ISSUE 50 MILLION A SHARES AT OFFER PRICE TO BE DETERMINED Source text for Eikon: Further company ...
- Reuters•2 months ago
HK stocks end firmer in line with China; MSCI move supports
* Hang Seng index ends up 0.6 pct China Enterprises index HSCE rises 1.2 percent HSI financial sub-index up 0.7 pct, property 0.4 pct higher * MSCI to quadruple weighting of A-shares in global benchmarks ...
- Reuters•2 months ago
BRIEF-CSPC Pharmaceutical Group's Shanghai Runshi Enters Agreements With Shanghai Institute Of Materia Medica
Feb 26 (Reuters) - CSPC Pharmaceutical Group Ltd: * SHANGHAI RUNSHI PHARMA TECHNOLOGY CO ENTERED INTO FOUR AGREEMENTS WITH SHANGHAI INSTITUTE OF MATERIA MEDICA * SHANGHAI RUNSHI AGREED TO PAY TO SIMM UPFRONT ...
- Reuters•3 months ago
BRIEF-CSPC Pharmaceutical Says Cetrain Financial Media Reported Co Indicated 20 Pct-30 Pct Profit Growth For FY19
Jan 10 (Reuters) - CSPC Pharmaceutical Group Ltd: * CSPC PHARMACEUTICAL SAYS CETRAIN FINANCIAL MEDIA REPORTED THAT COMPANY INDICATED A TARGET GUIDANCE OF 20%-30% PROFIT GROWTH OF GROUP FOR FY 2019 * BOARD ...
- Reuters•3 months ago
BRIEF-CSPC Pharmaceutical Group Unit To Acquire All Shares In Yong Shun
Jan 7 (Reuters) - CSPC Pharmaceutical Group Ltd: * DRAGON MERIT WILL ACQUIRE ALL ISSUED SHARES IN YONG SHUN FOR RMB252.9 MILLION Source text for Eikon: Further company coverage:
- Reuters•3 months ago
BRIEF-CSPC Pharmaceutical Group Unit Entered Agreement With Hangzhou Innogate Pharma
Jan 4 (Reuters) - CSPC Pharmaceutical Group Ltd: * UNIT ENTERED AGREEMENT WITH HANGZHOU INNOGATE PHARMA * AGGREEMENT TO CO-DEVELOP 5 SMALL-MOLECULE COMPOUNDS DEVELOPED BY HANGZHOU INNOGATE & STRATEGIC ...
- Reuters•4 months ago
BRIEF-CSPC Pharmaceutical Group'S Unit Enters Agreement With I-Mab Biopharma (Shanghai) Co
Dec 17 (Reuters) - CSPC Pharmaceutical Group Ltd: * UNIT ENTERED INTO AN AGREEMENT WITH I-MAB BIOPHARMA (SHANGHAI) CO., LTD. * CSPC BAIKE AGREED TO PAY UPFRONT PAYMENT OF RMB15 MILLION & DEVELOPMENT MILESTONE ...
- Reuters•5 months ago
BRIEF-Cspc Pharmaceutical Group Says Product Candidate "Almb-0166" Granted Orphan-Drug Designation By U.S. FDA
Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd: * GROUP'S PRODUCT CANDIDATE "ALMB-0166" GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA Source text for Eikon: Further company coverage:
- Reuters•5 months ago
BRIEF-Cspc Pharmaceutical Group Says "Tirofiban Hydrochloride And Sodium Chloride Injection" Granted Drug Registration Approval
Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd: * "TIROFIBAN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" GRANTED DRUG REGISTRATION APPROVAL * APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ...
- Reuters•5 months ago
BRIEF-CSPC Pharmaceutical Group's "Amoxicillin Capsules" Granted Approval By NMPA
Nov 26 (Reuters) - CSPC Pharmaceutical Group Ltd: * GROUP'S "AMOXICILLIN CAPSULES" GRANTED APPROVAL BY NMPA FOR PASSING CONSISTENCY EVALUATION Source text for Eikon: Further company coverage:...
- Reuters•5 months ago
BRIEF-CSPC Pharmaceutical Group Posts 9-Mth Profit Attributable Of HK$2.73 Bln
Nov 19 (Reuters) - CSPC Pharmaceutical Group Ltd: * 9-MONTH PROFIT ATTRIBUTABLE TO SHAREHOLDERS HK$2.73 BILLION VERSUS HK$2.04 BILLION * 9-MONTH TOTAL REVENUE HK$15.85 BILLION VERSUS HK$11.21 BILLION Source ...
- Reuters•6 months ago
BRIEF-Cspc Pharmaceutical Enters License Deal With Sinocelltech For Anti-CD20 Monoclonal Antibody
Oct 8 (Reuters) - CSPC Pharmaceutical Group Ltd: * ENTERS DEAL WITH SINOCELLTECH TO LICENSE AND COMMERCIALIZE ANTI- CD20 MONOCLONAL ANTIBODY FOR INJECTION DEVELOPED BY SINOCELLTECH * CO TO PAY SINOCELLTECH ...
- Zacks•7 months ago
Verastem Out-Licenses China Rights to Cancer Drug Copiktra
Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.
- Reuters•7 months ago
BRIEF-CSPC Pharmaceutical Announces Exclusive Product License Agreement With Verastem Inc
Sept 26 (Reuters) - CSPC Pharmaceutical Group Ltd: * ENTERED INTO AN EXCLUSIVE PRODUCT LICENSE AND COLLABORATION AGREEMENT WITH VERASTEM, INC * DEAL IN RELATION TO DEVELOPMENT AND COMMERCIALIZATION OF ...
- Reuters•7 months ago
BRIEF-CSPC Pharmaceutical Group Ltd And Verastem Oncology Sign Exclusive License Agreement
Sept 25 (Reuters) - CSPC Pharmaceutical Group Ltd: * CSPC PHARMACEUTICAL GROUP LIMITED AND VERASTEM ONCOLOGY SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF COPIKTRA™ (DUVELISIB) ...
- Business Wire•7 months ago
CSPC Pharmaceutical Group Limited and Verastem Oncology Sign Exclusive License Agreement for the Development and Commercialization of COPIKTRA™ (duvelisib) in China
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, and CSPC Pharmaceutical Group Limited (1093.HK) (CSPC), a leading pharmaceutical company in China, today announced their entry into an exclusive licensing agreement for CSPC to develop and commercialize Verastem Oncology’s COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in China. CSPC will have the right to collaborate with Verastem Oncology on certain global development and clinical trial activities and will share pro-rata in the cost.
- Reuters•8 months ago
BRIEF-CSPC Pharmaceutical Group Says Wang Jinxu Resigned As Executive Director
Aug 30 (Reuters) - CSPC Pharmaceutical Group Ltd: * WANG JINXU RESIGNED AS AN EXECUTIVE DIRECTOR * WANG JINXU REMAINS AS SENIOR VICE PRESIDENT OF COMPANY Source text for Eikon: Further company coverage:...
- Reuters•8 months ago
BRIEF-CSPC Pharmaceutical Group Appoints Wang Qingxi As An Executive Director
Aug 20 (Reuters) - CSPC Pharmaceutical Group Ltd: * WANG QINGXI WAS APPOINTED AS AN EXECUTIVE DIRECTOR Source text for Eikon: Further company coverage:
